RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY22 results · Jul–Sep 2021
RPG Life Sciences reported revenue from operations of ₹112.65 crore (up 16.0% from Q2 FY21) and net profit of ₹15.75 crore (up 41.3% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.65 | 97.13 | +16.0% | 108.13 | +4.2% |
| Other income | 0.71 | 0.04 | 18x | 0.41 | +73.2% |
| Total income | 113.36 | 97.17 | +16.7% | 108.54 | +4.4% |
| Profit before tax | 22.35 | 14.73 | +51.7% | 19.27 | +16.0% |
| Net profit for the period | 15.75 | 11.15 | +41.3% | 13.58 | +16.0% |
| EPS, basic (₹) | 9.52 | 6.74 | +41.2% | 8.21 | +16.0% |
| Net margin (%) | 14.0 | 11.5 | 12.6 |
Standalone
- Filed with BSE
- 01 Nov 2021, 15:22 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE